CASI Pharmaceuticals Inc (NASDAQ:CASI) President Larry Zhang bought 20,153 shares of the business’s stock in a transaction that occurred on Wednesday, July 22nd. The shares were bought at an average price of $1.90 per share, with a total value of $38,290.70. Following the completion of the purchase, the president now owns 20,153 shares in the company, valued at $38,290.70. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
Shares of CASI opened at $1.94 on Monday. The stock’s 50-day moving average price is $2.42 and its 200 day moving average price is $2.28. CASI Pharmaceuticals Inc has a 12-month low of $1.15 and a 12-month high of $3.82.
CASI Pharmaceuticals (NASDAQ:CASI) last announced its quarterly earnings data on Monday, May 11th. The biotechnology company reported ($0.09) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.11) by $0.02. The firm had revenue of $3.41 million for the quarter, compared to analyst estimates of $0.79 million. Analysts anticipate that CASI Pharmaceuticals Inc will post -0.3 EPS for the current fiscal year.
Institutional investors and hedge funds have recently bought and sold shares of the business. Wellesley Investment Partners LLC bought a new stake in CASI Pharmaceuticals in the 1st quarter valued at $30,000. Marshall Wace LLP bought a new position in shares of CASI Pharmaceuticals during the 1st quarter worth about $44,000. BNP Paribas Arbitrage SA boosted its position in shares of CASI Pharmaceuticals by 111.1% during the 1st quarter. BNP Paribas Arbitrage SA now owns 15,473 shares of the biotechnology company’s stock valued at $32,000 after acquiring an additional 8,142 shares in the last quarter. SG Americas Securities LLC bought a new stake in CASI Pharmaceuticals in the first quarter valued at about $37,000. Finally, Heritage Investors Management Corp raised its position in CASI Pharmaceuticals by 84.0% in the first quarter. Heritage Investors Management Corp now owns 18,579 shares of the biotechnology company’s stock worth $38,000 after purchasing an additional 8,484 shares in the last quarter. Hedge funds and other institutional investors own 21.54% of the company’s stock.
CASI Pharmaceuticals Company Profile
CASI Pharmaceuticals, Inc, a pharmaceutical company, develops pharmaceutical products and various therapeutics in China, the United States, and internationally. The company's product pipeline includes EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma.
Recommended Story: Is the QQQ ETF safe?
Receive News & Ratings for CASI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.